ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

Colorectal Cancer Clinical Trial

— ICARuS  

Official title:

ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01815359
• Other study ID #: 12-289
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 2013
• Est. completion date: September 2026

Study information

• Verified date: February 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 292
• Est. completion date: September 2026
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient's age 18 years or older, both genders.
• Clinical diagnosis of appendiceal or colorectal neoplasm with peritoneal mucinosis or metastasis.
• Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
• ECOG performance status = 1.
• Hematology: ANC = 1,500/ µL; Platelets > 75,000/ µL.
• Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of = 50ml/min.
• Adequate Hepatic function: Bilirubin less than 1.5mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg/dL).
• Women with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
• A man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the study.
• Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.
• Subjects with a history of endometrial cancer are eligible only if they presented with a stage lower than 1A and if the histology was a subtype other than poorly differentiated.

Exclusion Criteria:

• Subjects who have previously undergone intraperitoneal chemotherapy.
• Subjects with classical carcinoid
• Tumors of low malignant potential
• Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option.
• Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces.
• Women who are pregnant or lactating.
• Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
• Active coronary artery disease (defined as unstable angina or a positive cardiac stress test).
• Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment and/or were cleared by MSK cardiology.
• Uncontrolled hypertension defined as >140/90 and not cleared for surgery at the time of consent.
• New York Heart Association (NYHA) Class II or higher Congestive heart failure.
• Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
• History of cerebrovascular disease. that would limit study compliance or place the patient at unacceptable risk for participation in the study.
• Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study.
• Patients with known floxuridine, leucovorin ,or mitomycin allergy.
• Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
• Any condition that would preclude the ability to deliver appropriate IP therapy.
• Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
• Life expectancy < 12 weeks.

Related Conditions & MeSH terms

• Appendiceal Neoplasms
• Appendix Cancer
• Colorectal Cancer
• Fever
• Hyperthermia
• Neoplasms

Intervention

Procedure:
• Cytoreductive Surgery
Optimal Surgical Debulking

Drug:
• HIPEC with Mitomycin-C

• EPIC with FUDR and Leucovorin

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge (Consent and Follow up)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Commack (Consent and Follow up)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Consent and Follow up)	Harrison	New York
United States	University of Miami	Miami	Florida
United States	Memorial Sloan Kettering Monmouth (Consent and Follow up)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Consent and Follow up)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Memorial Sloan Kettering Nassau (Consent and Follow up)	Uniondale	New York

Sponsors (6)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Brigham and Women's Hospital, The Cleveland Clinic, University of Miami, University of Pittsburgh Medical Center, Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease-free survival	Documentation of tumor recurrence will be made based on surveillance CT/PET CT scans at time points as determined by attending radiologist, with clinical correlation from the treating physician.	3 years
Secondary	surgical toxicity grade 3 to 5	We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicites or chemotherapy related Grade 4 or 5 toxicities. Surgical morbidity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0	up to 60 days
Secondary	chemotherapy toxicity grade 3 to 5	We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicities or chemotherapy related Grade 4 or 5 toxicities.	up to 60 days

External Links

•   Memorial Sloan Kettering Cancer Center